Peter D Siersema1, Richard van Hillegersberg. 1. Department of Gastroenterology & Hepatology and Surgery, University Medical Center Utrecht, The Netherlands. p.d.siersema@umcutrecht.nl
Abstract
PURPOSE OF REVIEW: This article reviews developments in the treatment of locally advanced esophageal cancer with surgery and chemoradiation published in 2007. RECENT FINDINGS: Overall long-term survival is the same for patients after transhiatal or transthoracic esophagectomy. The pathology report of the resected specimen should contain information on lymph node status, such as size, location and lymph node ratio. If surgery is performed in patients with advanced esophageal cancer, there is small survival advantage if combined with neoadjuvant therapy, that is chemoradiation. Prognostic factors are a good performance status, a major response to chemoradiation and an early metabolic response with fluorine-18 fluorodeoxyglucose PET. Definitive chemoradiation may have similar results as combination treatment including surgery in selected patients with esophageal squamous cell cancer. Salvage surgery should be considered if definitive chemoradiation fails, provided that an R0 resection can be performed. Nutritional status is a prognostic factor in patients undergoing treatment of esophageal cancer. SUMMARY: In 2007, refinements of the nodal status in the tumor, node, metastasis system were proposed. Chemoradiation followed by surgery is increasingly being used in patients with advanced esophageal cancer. Evidence suggests that definitive chemoradiation could be a reliable treatment option in selected patients with esophageal squamous cell cancer.
PURPOSE OF REVIEW: This article reviews developments in the treatment of locally advanced esophageal cancer with surgery and chemoradiation published in 2007. RECENT FINDINGS: Overall long-term survival is the same for patients after transhiatal or transthoracic esophagectomy. The pathology report of the resected specimen should contain information on lymph node status, such as size, location and lymph node ratio. If surgery is performed in patients with advanced esophageal cancer, there is small survival advantage if combined with neoadjuvant therapy, that is chemoradiation. Prognostic factors are a good performance status, a major response to chemoradiation and an early metabolic response with fluorine-18 fluorodeoxyglucose PET. Definitive chemoradiation may have similar results as combination treatment including surgery in selected patients with esophageal squamous cell cancer. Salvage surgery should be considered if definitive chemoradiation fails, provided that an R0 resection can be performed. Nutritional status is a prognostic factor in patients undergoing treatment of esophageal cancer. SUMMARY: In 2007, refinements of the nodal status in the tumor, node, metastasis system were proposed. Chemoradiation followed by surgery is increasingly being used in patients with advanced esophageal cancer. Evidence suggests that definitive chemoradiation could be a reliable treatment option in selected patients with esophageal squamous cell cancer.
Authors: Juliana Yang; Ali A Siddiqui; Thomas E Kowalski; David E Loren; Ammara Khalid; Ayesha Soomro; Syed M Mazhar; Julian Rosé; Laura Isby; Michel Kahaleh; Ankush Kalra; Alex M Sarkisian; Nikhil A Kumta; Jose Nieto; Reem Z Sharaiha Journal: Surg Endosc Date: 2016-08-05 Impact factor: 4.584
Authors: Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Norma E Farrow; Chi-Fu J Yang; Thomas A D'Amico; David H Harpole Journal: Ann Thorac Surg Date: 2019-07-26 Impact factor: 4.330
Authors: Scarlet Nazarian; Ioannis Gkouzionis; Michal Kawka; Marta Jamroziak; Josephine Lloyd; Ara Darzi; Nisha Patel; Daniel S Elson; Christopher J Peters Journal: JAMA Surg Date: 2022-09-07 Impact factor: 16.681
Authors: G Ma; K Kawamura; Y Shan; S Okamoto; Q Li; M Namba; M Shingyoji; Y Tada; K Tatsumi; K Hiroshima; H Shimada; M Tagawa Journal: Cancer Gene Ther Date: 2014-01-17 Impact factor: 5.987
Authors: G Ma; K Kawamura; Q Li; S Okamoto; N Suzuki; H Kobayashi; M Liang; Y Tada; K Tatsumi; K Hiroshima; H Shimada; M Tagawa Journal: Cancer Gene Ther Date: 2010-08-06 Impact factor: 5.987